We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Federal officials are said to be examining whether Moderna’s COVID-19 vaccine is linked with higher risks of heart inflammation in younger people than once thought, possibly delaying the shot receiving authorization for adolescents. Read More
AstraZeneca said its monoclonal antibody treatment AZD7442 was shown to reduce the risk of developing COVID-19 symptoms by 77 percent vs. placebo in a phase 3 study — and it plans to use the findings to support global Emergency Use Authorizations and conditional approvals. Read More
The Biden administration yesterday rolled out a plan to offer booster shots to people who are fully vaccinated against SARS-CoV2 with mRNA vaccines starting on Sept. 20. Read More
Pfizer and BioNTech have submitted data to the FDA for approval of a third — or booster — dose of the their COVID-19 vaccine in healthy adults. Read More
An advisory panel assembled by the Centers for Disease Control and Prevention (CDC) voted unanimously on Friday to endorse the FDA’s expanded Emergency Use Authorizations allowing a third dose of the Pfizer/BioNTech and Moderna COVID-19 vaccines for certain immunocompromised individuals. Read More
The UK has ordered an additional 35 million booster doses of the Pfizer/BioNTech COVID-19 vaccine after Pfizer raised the costs due to rising demand. Read More
Expanding its existing Solidarity trial, the World Health Organization (WHO) will test three additional anti-inflammatory drugs as potential treatments for COVID-19. Read More
The FDA is poised to authorize a booster dose of the Pfizer/BioNTech or Moderna COVID-19 vaccines for immunocompromised people as soon as today. Read More
The former director of NIH’s Biomedical Advanced Research and Development Authority (BARDA), Rick Bright, has settled his whistleblower complaint that he was retaliated against by HHS for pushing for a more robust response in the early days of the COVID-19 pandemic. Read More
Moderna’s COVID-19 vaccine may be more effective than the Pfizer-BioNTech vaccine at protecting against variants of the coronavirus that causes COVID-19, two “preprint,” nonpeer-reviewed studies suggest. Read More